“global Single Lead ECG Equipment Market is anticipated to surpass USD 450 Million by 2020”, says Visiongain

07 November 2019

Visiongain has launched a new pharma report “Single Lead ECG Equipment Market Report” Prospects by Indication {Syncope, Arrhythmia (Atrial Fibrillation, Bradycardia, Tachycardia), Other Indications}, End users {Hospitals & Clinics, Home-care, Ambulatory Surgical Centers (ASCs)}, and Geography.

Global Single Lead ECG Equipment market is projected to grow on account of high prevalence of atrial fibrillation, advent of technology with respect to mobile ECG, and government regulations in the favor of remote monitoring devices among other contributing growth factors. The global market is projected to grow at a lucrative CAGR of ~5% over the forecast period from 2020 to 2030 and is anticipated to surpass USD 450 Million by 2020.

An ECG or electrocardiogram is a record of the heart's electrical activity. There are different types of ECG, but the most widely used is the single-lead ECG. By using ECG, it is possible to assess multiple heart problems and anomalies. This lets the doctor determine the patient's appropriate treatment.

The growing factors such as the increased prevalence of chronic as well as cardiovascular disease, increasing geriatric population, adoption of advanced technology, knowledge of cardiovascular disease and others, the single-lead ECG equipment market is anticipated to grow during the forecast period.

With the growing popularity of home care, these applications are capable of gaining significant traction in the foreseeable future due to a shift in direction towards personalized health monitoring solutions. Also, changing cardiac assessment preferences to self-triage before selecting complicated analytical systems contribute to the advent of single-lead ECG smartphone and mobile-based monitoring, thereby driving the market.

However, some entities combine mobile interoperability with ECG monitoring devices to provide users with immediate and easy access to ECG waveforms. These activities allow patients to experience improvement in the treatment of cardiovascular disease. Such advances in technology are likely to boost market growth over the forecast period.

To attract consumers and keep them interested along with consequent acceptance, market participants are engaged in developing an innovative product. Issues faced include the need for information management systems so that findings and evaluation can be communicated directly with physicians. Nonetheless, customer centricity-based programs are expected to reduce the effects of such challenges.

Due to ongoing developments in-home and outpatient health care in the region, North America dominated the global lead ECG equipment market in 2018. Moreover, due to the increased incidence of cardiovascular diseases, this region is experiencing a high mortality rate, which in turn increases the demand for such home-use technology in the coming years.

On the other hand, during the forecast period, Asia Pacific is likely to witness the fastest growth. Emerging economies, wearable devices' growing popularity, continuously evolving infrastructure, and presence of target population are among the local market's primary growth stimulus.

Markets in developing economies such as India are growing to build healthcare infrastructure and provide advanced primary healthcare services through partnerships with the government. Increasing consumer inclination towards mobile phone connected devices is also anticipated to fuel market growth over the forecast period.

Some of the major players operating in this industry are AliveCor, Inc., Ambisea Technology Corp. Ltd., CONTEC MEDICAL SYSTEMS CO. LTD., DailyCare BioMedical, Inc., Dimetek Digital Medical Technologies, Ltd., DRE Medical, Inc., Eurocamina Lohman Technologies, Lohman Technologies, Longfian Scitech Co.Ltd, OMRON Corporation, Perlong Medical Equipment Co., Ltd, REKA Health Pte Ltd, Shenzhen Creative Industry Co., Ltd, SUZUKEN CO. LTD., Tianjin Chase Sun Pharmaceutical Group, VCOMIN TECHNOLOGY LIMITED, Zenicor Medical Systems, Qardio, Inc., Tianjin Chase Sun Pharmaceutical Group, Eurocamina among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021


Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021